NANJING, China, July 13, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that six of its latest research studies have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress. Among these, two have been selected as Proffered Papers—the congress's highest-profile oral presentation format, while four will be presented as posters, covering multiple tumor types such as extrapulmonary neuroendocrine carcinoma (EP‑NEC), biliary tract cancer (BTC), and relapsed/refractory multiple myeloma (RRMM). In addition, the Company has been granted a Late‑Breaking Abstract (LBA) status and plans to submit the full LBA abstract in September.
The ESMO Annual Congress is one of the most influential scientific conferences in oncology. The 2026 congress will take place in Madrid, Spain, from October 23 to 27, 2026. Proffered Papers are reserved for studies considered to have the greatest clinical significance and scientific innovation, while LBA features the latest clinical findings with breakthrough potential and the ability to change clinical practice. The selection of multiple Leads Biolabs' studies underscores the international academic community's strong recognition of the Company's clinical data and the value of its pipeline, further demonstrating its sustained innovation capabilities and expanding leadership in cancer immunotherapy. The full data from the selected studies will be released through the ESMO online abstract publication and during the congress.
Separately, the Company previously announced that Opamtistomig for first‑line non‑small cell lung cancer (1L NSCLC) has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), to be held in September 2026. The full abstract is scheduled to be published on the WCLC website on August 19.
Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "The acceptance of multiple studies at ESMO represents strong international recognition of Leads Biolabs' innovative capabilities and clinical development achievements, and marks another important step in our journey toward becoming a leading global innovator in drug development. Opamtistomig continues to demonstrate encouraging depth of responses, favorable survival trends, and a well-tolerated safety profile across multiple tumor types, further reinforcing its strategic positioning as an IO 2.0 pan‑tumor backbone therapy. Meanwhile, LBL‑034 further validates the global competitiveness of our proprietary LeadsBody platform in the TCE field. Looking ahead, we remain committed to advancing global registrational clinical development and commercialization of our core assets, with the goal of bringing breakthrough therapies to more patients worldwide as quickly as possible."